Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases

References

• Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37(1):54–70.
   PubMed Web of Science ®Google Scholar
• ten Freyhaus H, Dumitrescu D, Bovenschulte H, Erdmann E, Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pul-monary arterial hypertension. Clin Res Cardiol. 2009;98(4): 265–7.
   Google Scholar
• Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J. 2010;51(4):272–6.
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JH, Distler 0. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050.
   Google Scholar
• Denton CP, Nihtyanova SI, Varga J, et al. Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy. Arthritis Rheum. 2010;62(S10): Abstract 566.
   Google Scholar
• Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclero-sis: results of a 1-year, phase Ha, single-arm, open-label clinical trial. Ann Rheum Dis. 2011.
   Google Scholar
• Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56(1): 311–22.
   PubMed Web of Science ®Google Scholar
• Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum. 2004;50(5):1578–85.
   Google Scholar
• Bhattacharyya S, Ishida W, Wu M, et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene. 2009;28(10):1285–97.
   PubMed Web of Science ®Google Scholar
• Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One. 2008;3(1):e1452.
   PubMed Web of Science ®Google Scholar
• Asano Y, Stawski L, Hant F, et al. Endothelial Hi! deficiency impairs vascular homeostasis: a role in scleroderma vasculopa-thy. Am J Pathol. 2010;176(4):1983–98.
   PubMed Web of Science ®Google Scholar
• Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 1999; 42(5):930–41.
   Google Scholar
• Kubo M, Czuwara-Ladykowska J, Moussa 0, et al. Persistent down-regulation of Flil, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003;163(2):571–81.
   Google Scholar
• Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54(7):2271–9.
   Google Scholar
• Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Tro-janowska M. Transcription factor Hi! regulates collagen fibril-logenesis in mouse skin. Mol Cell Biol. 2009;29(2):425–34.
   Google Scholar
• Asano Y, Trojanowska M. Phosphorylation of Flil at threonine 312 by protein kinase C delta promotes its interaction with p300/ CREB-binding protein-associated factor and subsequent acety-lation in response to transforming growth factor beta. Mol Cell Biol. 2009;29(7):1882–94.
   PubMed Web of Science ®Google Scholar
• Asano Y, Czuwara J, Trojanowska M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Flil by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem. 2007;282(48):34672–83.
   Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–51.
   PubMed Web of Science ®Google Scholar
• Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4(6):963–71.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114(3):709–18.
   PubMed Web of Science ®Google Scholar
• Fietta A, Bardoni A, Salvini R, et al. Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Res 'Ther. 2006;8(6):R160.
   PubMed Web of Science ®Google Scholar
• Kucharz RI, Grucka-Mamczar E, Mamczar A, Brzezinska-Wcislo L. Acute-phase proteins in patients with systemic sclerosis. Clin Rheumatol. 2000;19(2):165–6.
   PubMed Web of Science ®Google Scholar
• Azuma M, Nishioka Y, Aono Y, et al. Role of alphal-acid gly-coprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med. 2007; 176(12):1243–50.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kosto-poulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008; 47(5):735–7.
   PubMed Web of Science ®Google Scholar